Table 3 Three-month transition probabilities between visual acuity states for dexamethasone and aflibercept
From: Cost-effectiveness of dexamethasone compared with aflibercept in naïve diabetic macular edema
Visual acuity | > 20/40 | ≤ 20/40 to > 20/80 | ≤ 20/80 to > 20/200 | ≤ 20/200 to > 20/400 | ≤ 20/400 |
|---|---|---|---|---|---|
Dexamethasone | |||||
> 20/40 | 0.9863 | 0.0107 | 0.0030 | 0 | 0 |
≤ 20/40 to > 20/80 | 0.0979 | 0.8884 | 0.0107 | 0.0030 | 0 |
≤ 20/80 to > 20/200 | 0 | 0.0979 | 0.8884 | 0.0107 | 0.0030 |
≤ 20/200 to > 20/400 | 0 | 0 | 0.0979 | 0.8884 | 0.0137 |
≤ 20/400 | 0 | 0 | 0 | 0.0979 | 0.9021 |
Aflibercept | |||||
> 20/40 | 0.9199 | 0.0542 | 0.0259 | 0 | 0 |
≤ 20/40 to > 20/80 | 0.0153 | 0.9046 | 0.0542 | 0.0259 | 0 |
≤ 20/80 to > 20/200 | 0 | 0.0153 | 0.9046 | 0.0542 | 0.0259 |
≤ 20/200 to > 20/400 | 0 | 0 | 0.0153 | 0.9046 | 0.0801 |
≤ 20/400 | 0 | 0 | 0 | 0.0153 | 0.9847 |